9OA8 image
Deposition Date 2025-04-19
Release Date 2025-06-18
Last Version Date 2025-06-25
Entry Detail
PDB ID:
9OA8
Title:
Cryo-EM structure of KCa3.1/calmodulin channel in complex with NS309
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Rattus norvegicus (Taxon ID: 10116)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.59 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Intermediate conductance calcium-activated potassium channel protein 4
Gene (Uniprot):KCNN4
Chain IDs:A, B, C, D
Chain Length:378
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Calmodulin-1
Gene (Uniprot):Calm1
Chain IDs:E, F, G, H
Chain Length:146
Number of Molecules:4
Biological Source:Rattus norvegicus
Primary Citation
Structural basis for the subtype-selectivity of K Ca 2.2 channel activators.
Res Sq ? ? ? (2025)
PMID: 40470184 DOI: 10.21203/rs.3.rs-6568445/v1

Abstact

Small-conductance (KCa2.2) and intermediate-conductance (KCa3.1) Ca2+-activated K+ channels are gated by a Ca2+-calmodulin dependent mechanism. NS309 potentiates the activity of both KCa2.2 and KCa3.1, while rimtuzalcap selectively activates KCa2.2. Rimtuzalcap has been used in clinical trials for the treatment of spinocerebellar ataxia and essential tremor. We report cryo-electron microscopy structures of KCa2.2 channels bound with NS309 and rimtuzalcap, in addition to KCa3.1 channels with NS309. The different conformations of calmodulin and the cytoplasmic HC helices in the two channels underlie the subtype-selectivity of rimtuzalcap for KCa2.2. Calmodulin's N-lobes in the KCa2.2 structure are far apart and undergo conformational changes to accommodate either NS309 or rimtuzalcap. Calmodulin's Nlobes in the KCa3.1 structure are closer to each other and are constrained by the HC helices of KCa3.1, which allows binding of NS309 but not of the bulkier rimtuzalcap. These structures provide a framework for structure-based drug design targeting KCa2.2 channels.

Legend

Protein

Chemical

Disease

Primary Citation of related structures